...
首页> 外文期刊>Journal of biomaterials and nanobiotechnology. >&i&In-Silico&/i& Validation and Development of Chlorogenic Acid (CGA) Loaded Polymeric Nanoparticle for Targeting Neurodegenerative Disorders
【24h】

&i&In-Silico&/i& Validation and Development of Chlorogenic Acid (CGA) Loaded Polymeric Nanoparticle for Targeting Neurodegenerative Disorders

机译:& i&在-In-silico& / i&绿原酸(CGA)加载聚合物纳米粒子用于靶向神经变性障碍的验证和发展

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Recent decades witnessed a significant growth in terms of phytocompounds based therapeutics, extensively explored for almost all types of existing disorders. They have also been widely investigated in Neurodegenerative disorders (NDDs) and Chlorogenic acid (CGA), a polyphenolic compound having potential anti-inflammatory and anti-oxidative properties, emerged as a promising compound in ameliorating NDDs. Owing to its poor stability, bioavailability and release kinetics, CGA needed a suitable nanocarrier based pharmaceutical design for targeting NDDs. Objective: The current study is aimed at the in-silico validation of CGA as an effective therapeutic agent targeting various NDDs followed by the fabrication of polymeric nanoparticles-based carrier system to overcome its pharmacological limitations and improve its stability. Methods: A successful in-silico validation using molecular docking techniques along with synthesis of CGA loaded polymeric nanoparticles (CGA-NPs) by ionic gelation method was performed. The statistical optimisation of the developed CGA-NPs was done by Box Behnken method and then the optimized formulation of CGA-NPs was characterised using particle size analysis (PSA), Transmission electron microscopy (TEM), Fourier Transform Infrared spectroscopy (FTIR) along with in-vitro release kinetics analysis. Results & Conclusion: The results attained exhibited average particle size of 101.9 ± 1.5 nm, Polydispersibility (PDI) score of 0.065 and a ZP of − 17.4 mV. On a similar note, TEM results showed a size range of CGA-NPs between 90 - 110 nm with a spherical shape of NPs. Also, the data from in-vitro release kinetics showed a sustained release of CGA from the NPs following the first-order kinetics suggesting the appropriate designing of nanoformulation.
机译:背景:最近几十年目睹了基于植物化合物的治疗方法的显着增长,广泛探索了几乎所有类型的现有障碍。它们还被广泛研究在神经变性障碍(NDDS)和绿原酸(CGA)中,具有潜在的抗炎和抗氧化性能的多酚化合物,其作为改善NDDS的有希望的化合物出现。由于其稳定性差,生物利用度和释放动力学差,CGA需要一种合适的基于纳米载体的药物设计,用于靶向NDD。目的:目前的研究旨在CGA作为靶向各种NDD的有效治疗剂的硅基核验证,然后制备基于聚合物纳米粒子的载体系统,以克服其药理学限制并提高其稳定性。方法:通过离子胶凝法进行使用分子对接技术的成功硅验证以及合成CGA负载的聚合物纳米颗粒(CGA-NPS)。开发的CGA-NPS的统计优化由盒BEHNKEN方法进行,然后使用粒度分析(PSA),透射电子显微镜(TEM),傅里叶变换红外光谱(FTIR)进行了CGA-NP的优化配方。体外释放动力学分析。结果求和结论:达到的结果表明平均粒度为101.9±1.5nm,多分散性(PDI)得分为0.065和ZP的− 17.4 mV。在类似的备注上,TEM结果在90-110nm之间显示了CGA-NP的尺寸范围,具有NP的球形。此外,来自体外释放动力学的数据显示,在一阶动力学之后,纳米型测量的一定动力学,从NPS显示CGA的持续释放。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号